{"title":"2021年乳腺癌全身治疗临床试验最重要的结果","authors":"S. Tjulandin, М.В. Stenina, М.А. Frolova","doi":"10.31917/2301009","DOIUrl":null,"url":null,"abstract":"This article discusses the most significant results of recent studies of various issues of systemic therapy for both early and metastatic breast cancer. The high efficacy of a number of experimental regimens and drugs can serve as the basis for their early introduction into clinical practice. On the other hand, given several possible treatment options in one setting, it is required to search for predictive biomarkers, as well as to determine the most optimal sequence of standard and new therapy regimens.","PeriodicalId":101072,"journal":{"name":"Reports of Practical Oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The most important results of clinical trials for breast cancer systemic therapy in 2021\",\"authors\":\"S. Tjulandin, М.В. Stenina, М.А. Frolova\",\"doi\":\"10.31917/2301009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This article discusses the most significant results of recent studies of various issues of systemic therapy for both early and metastatic breast cancer. The high efficacy of a number of experimental regimens and drugs can serve as the basis for their early introduction into clinical practice. On the other hand, given several possible treatment options in one setting, it is required to search for predictive biomarkers, as well as to determine the most optimal sequence of standard and new therapy regimens.\",\"PeriodicalId\":101072,\"journal\":{\"name\":\"Reports of Practical Oncology\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reports of Practical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31917/2301009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reports of Practical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31917/2301009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The most important results of clinical trials for breast cancer systemic therapy in 2021
This article discusses the most significant results of recent studies of various issues of systemic therapy for both early and metastatic breast cancer. The high efficacy of a number of experimental regimens and drugs can serve as the basis for their early introduction into clinical practice. On the other hand, given several possible treatment options in one setting, it is required to search for predictive biomarkers, as well as to determine the most optimal sequence of standard and new therapy regimens.